Tag: Arrowhead

Clinical Trials, Research and Development

Arrowhead reports positive data from liver drug, but company’s shares slide

January 9, 2023

Via: Biopharma Dive

Arrowhead’s drug, called fazirsiran, is designed to treat alpha-1 antitrypsin deficiency, a genetic condition in which a mutant form of the namesake protein accumulates in liver cells, causing fibrosis and cirrhosis. Alpha-1 antitrypsin, or AAT, deficiency has become a target […]